Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metoclopramide versus ondansetron for etomidate injection pain
IRCT20160307026950N32Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of metoclopramide, ondansetron and etomidate in Injection site pain (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Severe pain due to etomidate injection. Started Apr 2021; status: completed.
02
Drugs
metoclopramideondansetronetomidate
03
Conditions
Injection site pain
Beyond the preview
Go deeper on IRCT20160307026950N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N32.